A system comprising a drug delivery device and a cartridge provided with a bung and and a method of identifying the cartridge

The present invention relates to a bung (20), to a drug containing cartridge (10) and to a drug delivery device, wherein the bung (20) comprises a coding feature (28) for carrying information regarding at least one of the cartridge (10) and the content of the cartridge (10). Furthermore, it relates to a method for identifying a cartridge (10) containing a medicinal product.

A method for producing a glass article having high hydrolytic resistance is provided. A glass tube consisting of borosilicate glass and having an Al.sub.2O.sub.3 content of less than 1 weight-%, a ZrO.sub.2 content of 2-12 weight-%, and a glass transition temperature T.sub.g is reshaped into a glass article and is subsequently subjected to a thermal post-treatment. To reduce the alkali release of the glass article, the glass article is subjected to a treatment temperature of T.sub.B≥T.sub.g+5° K over a treatment time of t.sub.B≥5 min and is subsequently cooled during the thermal post-treatment.

According to one embodiment, a glass composition may include from 67 mol. % to about 75 mol. % SiO.sub.2; from about 6 mol. % to about 10 mol. % Al.sub.2O.sub.3; and from about 5 mol. % to about 12 mol. % alkali oxide. The alkali oxide may include K.sub.2O in an amount less than or equal to 0.5 mol. %. The glass composition may further include from about 9 mol. % to about 15 mol. % of alkaline earth oxide. The alkaline earth oxide may include greater than about 0 mol. % and less than or equal to 3 mol. % MgO, from 2 mol. % to about 7 mol % CaO, at least one of SrO and BaO. The glass composition may further include less than 1 mol. % B.sub.2O.sub.3. A ratio of a concentration of MgO to the sum of the concentration of divalent cations (MgO:ΣRO) may be less than 0.3.

A medication device with a cartridge or syringe having a longitudinal axis and contains a medicament, a housing receiving the cartridge or syringe and having a center axis, and with an RFID device comprising at least one RFID chip with a first antenna, at least one RFID readout unit with a second antenna), wherein the RFID chip is associated with the cartridge or syringe or housing and the RFID readout unit is associated accordingly with the housing or cartridge or syringe. The medication device is characterized in that the first antenna of the RFID chip and the second antenna of the RFID readout unit are each embodied as a coil and aligned such that they are coaxial with one another and with the longitudinal axis as well as with the center axis.

A pharmaceutical packaging is provided including a glass, comprising at least the following components (given in mol % on oxide basis): SiO.sub.2:59-84, Al.sub.2O.sub.3:7-18.5, CaO:1-25, SrO:0-6.5, BaO:0-5, ZrO.sub.2:0-3, TiO.sub.2:0-5, B.sub.2O.sub.3:0-1, wherein the ratio (CaO+SrO+BaO)/Al.sub.2O.sub.3<2.8, wherein the ratio (CaO+SrO+BaO)/SiO.sub.2≦0.39, wherein the hydrolytic resistance according to DIN ISO 720 is class HGA 1, and wherein the glass, apart from unavoidable contaminations, is free of alkali oxides and magnesium oxides.

A strengthened glass container or vessel such as, but not limited to, vials for holding pharmaceutical products or vaccines in a hermetic and/or sterile state. The strengthened glass container undergoes a strengthening process that produces compression at the surface and tension within the container wall. The strengthening process is designed such that the tension within the wall is great enough to ensure catastrophic failure of the container, thus rendering the product unusable, should sterility be compromised by a through-wall crack. The tension is greater than a threshold central tension, above which catastrophic failure of the container is guaranteed, thus eliminating any potential for violation of pharmaceutical integrity.

The present invention relates to a method for manufacturing glass containers for pharmaceutical use. This method allows obtaining containers with a low degree of alkalinity. In some preferred embodiments the process allows the manufacture of sterile containers and substantially free of particles ready to be used by the pharmaceutical industry.

Various aspects of this patent document relate cannabinoid anions including methods to produce cannabinoid anions, compositions comprising cannabinoid anions, containers that contain compositions comprising cannabinoid anions, and methods to consume cannabinoid anions.

Vials and vial assemblies for storing a medicament in low temperature environments are provided. In one exemplary embodiment, a vial is provided that includes a base portion and a finish portion. The finish portion has an outer surface and an inner surface, in which the inner surface defines a channel that is configured to receive a first portion of a deformable sealing member. The finish portion on the outer surface thereof includes a surface feature that is configured to engage with a second portion of the deformable sealing member. The surface feature is configured to remain engaged with the second portion of the deformable sealing member when the deformable sealing member contracts from a first configuration to a second configuration, thereby maintaining a seal between the finish portion and the deformable sealing member.

The present invention relates in general to the improved containment of biological fluids. In particular, a method and apparatus for collection and preservation of fluid samples in accordance with the present invention results in collection of semen having improved viability both at the time of collection and after storage. The disclosed methods and apparatuses methods support a wide variety of applications for containment of biological fluids related to human and veterinary medicine including, but not limited to, human reproductive medicine and animal husbandry.